» Articles » PMID: 17687559

Increased Caveolin-1 Expression Precedes Decreased Expression of Occludin and Claudin-5 During Blood-brain Barrier Breakdown

Overview
Specialty Neurology
Date 2007 Aug 10
PMID 17687559
Citations 110
Authors
Affiliations
Soon will be listed here.
Abstract

The significance of caveolin-1, a major constituent of caveolae, and the tight junction proteins occludin and claudin-5 in early blood-brain barrier (BBB) breakdown was assessed by sequential demonstration of the expression of these proteins over a period of 12 h to 6 days post-lesion in the rat cortical cold injury model. Pial and intracerebral vessels of control rats showed punctuate endothelial immunoreactivity for caveolin-1 and caveolin-2, while claudin-5 and occludin were localized as longitudinal strands in endothelium. During the early phase of BBB breakdown following injury at 12 h and on day 2, western blot analyses detected a significant increase in caveolin-1 expression at the lesion site while immunohistochemistry showed that the caveolin-1 increase was localized to the endothelium of lesion vessels. Decreased expression of occludin occurred at the lesion site only on days 2 and 4 post-lesion while claudin-5 expression was decreased only on day 2. Dual labeling for fibronectin, a marker of BBB breakdown, and caveolin-1 or the tight junction proteins demonstrated that only lesion vessels with BBB breakdown showed a marked increase of caveolin-1, loss of occludin and reduced localization of claudin-5. The issue whether these alterations precede or follow BBB breakdown is uncertain; however, increased expression of caveolin-1 preceded the decreased expression of occludin and claudin-5. Thus caveolae and caveolin-1 have an important role in early BBB breakdown and could be potential therapeutic targets in the control of early brain edema.

Citing Articles

BMSCs-derived small extracellular vesicles antagonize cerebral endothelial Caveolin-1 driven autophagic degradation of tight-junction proteins to protect blood-brain barrier post-stroke.

Li Y, Quan X, Hu J, Han Y, Chen J, Zhou M Int J Biol Sci. 2025; 21(2):842-859.

PMID: 39781452 PMC: 11705626. DOI: 10.7150/ijbs.101937.


Unveiling the hidden connection: the blood-brain barrier's role in epilepsy.

Han J, Wang Y, Wei P, Lu D, Shan Y Front Neurol. 2024; 15:1413023.

PMID: 39206290 PMC: 11349696. DOI: 10.3389/fneur.2024.1413023.


Physiological and pathological roles of caveolins in the central nervous system.

Badaut J, Blochet C, Obenaus A, Hirt L Trends Neurosci. 2024; 47(8):651-664.

PMID: 38972795 PMC: 11324375. DOI: 10.1016/j.tins.2024.06.003.


Glial growth factor 2 treatment alleviates ischemia and reperfusion-damaged integrity of the blood-brain barrier through decreasing Mfsd2a/caveolin-1-mediated transcellular and Pdlim5/YAP/TAZ-mediated paracellular permeability.

Zhang X, Du W, Qian S, Lu X, Yu X, Fang H Acta Pharmacol Sin. 2024; 45(11):2241-2252.

PMID: 38902501 PMC: 11489722. DOI: 10.1038/s41401-024-01323-7.


From spreading depolarization to blood-brain barrier dysfunction: navigating traumatic brain injury for novel diagnosis and therapy.

van Hameren G, Aboghazleh R, Parker E, Dreier J, Kaufer D, Friedman A Nat Rev Neurol. 2024; 20(7):408-425.

PMID: 38886512 DOI: 10.1038/s41582-024-00973-9.